

Investor Relations

Like 5

Tweet 0

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August 5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net revenue of more than \$3.5 billion. For Investor Relations information on Valeant, [click here](#).



Vision and Eye Health

- Vision and Age
- Eye Infections & Irritations
- Diseases and Disorders
- Find a Doctor
- Eye Exam Check List

Products

- Contact Lenses
- Contact Lens Care
- Dry Eye Products
- Allergy/Redness Relief
- Rx Pharmaceutical
- Eye Vitamins
- Surgical Products
- Vision Accessories

Customer Support

- Contact Us
- Customer policies and forms
- Rebate Center
- Worldwide Locations

Legal

- Legal Notice
- Privacy Policy
- Safety Data Sheets (SDS)

Newsroom

- Careers
- Investor Relations
- Grants & Contributions

© 2015 Bausch & Lomb Incorporated.

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.